Key result
ICI use linked to ~4.4-fold higher risk of pericardial disease.
Why the study?
Data are limited regarding the occurrence, associations, and outcomes of pericardial effusions and pericarditis during or following treatment with immune checkpoint inhibitors.
Does treatment with immune checkpoint inhibitors increase the risk of developing pericarditis or moderate-to-large pericardial effusion in patients with cancer compared to matched controls not receiving immune checkpoint inhibitors?
Cohort (n=5,541)
Blindly adjudicated endpoints
No
Does treatment with immune checkpoint inhibitors increase the risk of developing pericarditis or moderate-to-large pericardial effusion in patients with cancer compared to matched controls not receiving immune checkpoint inhibitors?
Immune checkpoint inhibitor therapy is independently associated with a more than fourfold increased risk of pericarditis or moderate-to-large pericardial effusion, which in turn carries a trend toward increased mortality.
Answers are grounded in this paper and cite their sources.
May warrant enhanced pericardial surveillance in ICI recipients; leaves open causality and screening utility pending prospective data.
BACKGROUND: There are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis on or after treatment with immune checkpoint inhibitors (ICIs). METHODS: This was a retrospective study at a single academic center that compared 2842 consecutive patients who received ICIs with 2699 age- and cancer-type matched patients with metastatic disease who did not receive ICI. A pericardial event was defined as a composite outcome of pericarditis and new or worsening moderate or large pericardial effusion. The endpoints were obtained through chart review and were blindly adjudicated. To identify risk factors associated with a pericardial event, we compared patients who developed an event on an ICI with patients treated with an ICI who did not develop a pericardial event. Cox proportional-hazard model and logistical regression analysis were performed to study the association between ICI use and pericardial disease as well as pericardial disease and mortality. An additional 6-week landmark analysis was performed to account for lead-time bias. RESULTS: There were 42 pericardial events in the patients treated with ICI (n=2842) over 193 days (IQR: 64-411), yielding an incidence rate of 1.57 events per 100 person-years. There was a more than fourfold increase in risk of pericarditis or a pericardial effusion among patients on an ICI compared with controls not treated with ICI after adjusting for potential confounders (HR 4.37, 95% CI 2.09 to 9.14, p<0.001). Patients who developed pericardial disease while on an ICI had a trend for increased all-cause mortality compared with patients who did not develop a pericardial event (HR 1.53, 95% CI 0.99 to 2.36, p=0.05). When comparing those who developed pericardial disease after ICI treatment with those who did not, a higher dose of corticosteroid pre-ICI (>0.7 mg/kg prednisone) was associated with increased risk of pericardial disease (HR 2.56, 95% CI 1.00 to 6.57, p=0.049). CONCLUSIONS: ICI use was associated with an increased risk of development of pericardial disease among patients with cancer and a pericardial event on an ICI was associated with a trend towards increase in mortality.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2021) conducted a cohort in Metastatic cancer (n=5,541). Immune checkpoint inhibitors (ICIs) vs. Age- and cancer-type matched patients with metastatic disease not treated with ICIs was evaluated on Composite of pericarditis and new or worsening moderate or large pericardial effusion (HR 4.37, 95% CI 2.09 to 9.14, p=<0.001). Immune checkpoint inhibitor use was associated with a greater than fourfold increased risk of pericardial disease compared with controls not treated with ICIs.
Synapse has enriched 10 related papers. Consider them for comparative context: